Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

A third of patients with multiple myeloma (MM) have a preceding diagnosis of plasma cell proliferative disorder (PCPD), mostly monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM) or plasmacytoma. While autologous stem cell transplantation (SCT) improves survival in MM, it is not clear if patients with preceding PCPD have a different outcome. We identified 151 patients with preceding PCPD from among 804 patients undergoing SCT, and their outcomes were compared. The response rates, including complete responses, were similar between the groups. Patients with a preceding diagnosis of MGUS had longer time to progression (TTP; 27.5 months vs. 17.2 months, P = 0.01), and longer overall survival (OS) from transplant (80.2 months vs. 48.3 months, P = 0.03) compared to those with de novo myeloma. However no differences were seen among those with a preceding diagnosis of SMM or plasmacytoma in terms of TTP or OS from transplant when compared to those with de novo myeloma. Multivariate analysis indicated that the presence of MGUS prior to myeloma was prognostic for post-transplant relapse independent of other known risk factors. Patients with pre-existing MGUS prior to myeloma diagnosis have a better outcome following HDT, reflecting more indolent disease and a favourable biology than those presenting with de novo myeloma.

Original languageEnglish (US)
Pages (from-to)205-211
Number of pages7
JournalBritish Journal of Haematology
Volume141
Issue number2
DOIs
StatePublished - Apr 2008

Fingerprint

Stem Cell Transplantation
Plasma Cells
Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance
Plasmacytoma
Transplants
Survival
Multivariate Analysis
Recurrence

Keywords

  • Monoclonal gammopathies
  • Multiple myeloma
  • Stem cell transplantation
  • Survival

ASJC Scopus subject areas

  • Hematology

Cite this

@article{7856d97a0215414794b5cb767d984365,
title = "Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders",
abstract = "A third of patients with multiple myeloma (MM) have a preceding diagnosis of plasma cell proliferative disorder (PCPD), mostly monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM) or plasmacytoma. While autologous stem cell transplantation (SCT) improves survival in MM, it is not clear if patients with preceding PCPD have a different outcome. We identified 151 patients with preceding PCPD from among 804 patients undergoing SCT, and their outcomes were compared. The response rates, including complete responses, were similar between the groups. Patients with a preceding diagnosis of MGUS had longer time to progression (TTP; 27.5 months vs. 17.2 months, P = 0.01), and longer overall survival (OS) from transplant (80.2 months vs. 48.3 months, P = 0.03) compared to those with de novo myeloma. However no differences were seen among those with a preceding diagnosis of SMM or plasmacytoma in terms of TTP or OS from transplant when compared to those with de novo myeloma. Multivariate analysis indicated that the presence of MGUS prior to myeloma was prognostic for post-transplant relapse independent of other known risk factors. Patients with pre-existing MGUS prior to myeloma diagnosis have a better outcome following HDT, reflecting more indolent disease and a favourable biology than those presenting with de novo myeloma.",
keywords = "Monoclonal gammopathies, Multiple myeloma, Stem cell transplantation, Survival",
author = "Kumar, {Shaji K} and Dingli, {David M} and Martha Lacy and Angela Dispenzieri and Hayman, {Suzanne R.} and Buadi, {Francis K.} and Rajkumar, {S Vincent} and Litzow, {Mark R} and Morie Gertz",
year = "2008",
month = "4",
doi = "10.1111/j.1365-2141.2008.07069.x",
language = "English (US)",
volume = "141",
pages = "205--211",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders

AU - Kumar, Shaji K

AU - Dingli, David M

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Hayman, Suzanne R.

AU - Buadi, Francis K.

AU - Rajkumar, S Vincent

AU - Litzow, Mark R

AU - Gertz, Morie

PY - 2008/4

Y1 - 2008/4

N2 - A third of patients with multiple myeloma (MM) have a preceding diagnosis of plasma cell proliferative disorder (PCPD), mostly monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM) or plasmacytoma. While autologous stem cell transplantation (SCT) improves survival in MM, it is not clear if patients with preceding PCPD have a different outcome. We identified 151 patients with preceding PCPD from among 804 patients undergoing SCT, and their outcomes were compared. The response rates, including complete responses, were similar between the groups. Patients with a preceding diagnosis of MGUS had longer time to progression (TTP; 27.5 months vs. 17.2 months, P = 0.01), and longer overall survival (OS) from transplant (80.2 months vs. 48.3 months, P = 0.03) compared to those with de novo myeloma. However no differences were seen among those with a preceding diagnosis of SMM or plasmacytoma in terms of TTP or OS from transplant when compared to those with de novo myeloma. Multivariate analysis indicated that the presence of MGUS prior to myeloma was prognostic for post-transplant relapse independent of other known risk factors. Patients with pre-existing MGUS prior to myeloma diagnosis have a better outcome following HDT, reflecting more indolent disease and a favourable biology than those presenting with de novo myeloma.

AB - A third of patients with multiple myeloma (MM) have a preceding diagnosis of plasma cell proliferative disorder (PCPD), mostly monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM) or plasmacytoma. While autologous stem cell transplantation (SCT) improves survival in MM, it is not clear if patients with preceding PCPD have a different outcome. We identified 151 patients with preceding PCPD from among 804 patients undergoing SCT, and their outcomes were compared. The response rates, including complete responses, were similar between the groups. Patients with a preceding diagnosis of MGUS had longer time to progression (TTP; 27.5 months vs. 17.2 months, P = 0.01), and longer overall survival (OS) from transplant (80.2 months vs. 48.3 months, P = 0.03) compared to those with de novo myeloma. However no differences were seen among those with a preceding diagnosis of SMM or plasmacytoma in terms of TTP or OS from transplant when compared to those with de novo myeloma. Multivariate analysis indicated that the presence of MGUS prior to myeloma was prognostic for post-transplant relapse independent of other known risk factors. Patients with pre-existing MGUS prior to myeloma diagnosis have a better outcome following HDT, reflecting more indolent disease and a favourable biology than those presenting with de novo myeloma.

KW - Monoclonal gammopathies

KW - Multiple myeloma

KW - Stem cell transplantation

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=40949129226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949129226&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2008.07069.x

DO - 10.1111/j.1365-2141.2008.07069.x

M3 - Article

C2 - 18318761

AN - SCOPUS:40949129226

VL - 141

SP - 205

EP - 211

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -